Earlier this month, Perrigo shareholders spurned a hostile buyout attempt from Mylan. And now, the Netherlands-based company may have to go up against its former target if it wants to pursue a replacement buy.
The companies could find themselves sparring over drugmakers like California’s Impax Labs, Germany’s Stada or Israel’s Taro, Bloomberg Intelligence analyst Elizabeth Krutoholow told Bloomberg. And for Mylan, which has now been rejected by its past two targets–Perrigo and Sweden’s Meda before it–the stakes are high.
“They don’t have a lot of confidence from investors right now,” Krutoholow said. “They can’t afford to lose on their next bid.”
The way some analysts see it, though, Mylan’s failure to snag Perrigo was a good thing for the drugmaker, even if it’ll now face some heated competition in the M&A arena.
“We believe Mylan was overpaying for Perrigo and the long-term value of the merger was suspect, in our view,” Bernstein analyst Ronny Gal wrote in a recent note to clients, pointing out that the company could potentially go after Sanofi’s newly on-the-block generics business or Pfizer’s established products, should the pharma giant split into two following the close of its $160 billion merger with Allergan.
Both of those options come along with “lower risk and likely better returns, in our view,” he wrote.
Mylan may also find opportunity in Allergan’s proposed $40.5-billion-dollar pact to sell its generics unit to Teva, Nexthera Capital’s Chief Investment Officer, Ori Hershkovitz, told the news service. That tie-up will require the drugmakers to jettison some assets to clear antitrust hurdles, and Mylan may be able to pounce on them.
Perrigo CEO Joseph Papa, for his part has said the OTC specialist would be eyeing “consumer-facing assets.” And the company wasted no time striking a deal after freeing itself from Mylan’s grasp: Earlier this week, it announced a $380 million agreement to buy the U.S. rights to AstraZeneca’s Entocort, as well as an authorized generic that’s been marketed by Par Pharmaceuticals.
By Carly Helfand
Source: Fierce Pharma
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.